Allergan Assails Valeant

May 27 2014 | 12:36pm ET

In its battle to avoid being swallowed by rival Valeant Pharmaceuticals International, Allergan Inc. isn’t afraid to fight dirty.

The Botox-maker again blasted Valeant’s business model and alleges that its $46 billion hostile offer—backed by hedge fund Pershing Square Capital Management—is exaggerating the potential savings that could be achieved by a merger.

In a regulatory filing, Allergan said that fewer savings from research and development and tax structure were available. It also reiterated its fear that Valeant lacks transparency and that its acquisition model masks low sales growth and the market-share erosion suffered by the companies it buys.

“Valeant’s limited experience with large, global-scale products represents a material execution risk attempting to grow Allergan’s categories and launching significant new large products through existing channels,” Allergan said.

Allergan’s claims were backed by forensic accounting firms Alvarez & Marshal and FTI Consulting.

Earlier this month, Allergan rejected Valeant’s offer, saying it substantially undervalues the company.


In Depth

Q&A: Rotation Capital's Rothfleisch On SPAC 2.0

Aug 11 2017 | 7:43pm ET

Corporate actions have long been a staple of event-driven investors, but activity...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Star Mountain: Private Lending in the Lower Middle-Market

Aug 14 2017 | 4:45pm ET

Private credit has become one of the most popular alternative asset classes in recent...

 

From the current issue of